Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
AYTU | US
0.08
3.14%
Healthcare
Biotechnology
30/06/2024
13/04/2026
2.63
2.54
2.68
2.54
Aytu Biopharma Inc. a commercial-stage pharmaceutical company focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company operates into two segments Rx segment and Consumer Health segment. The Rx segment consisting of prescription pharmaceutical products sold through third party wholesalers. The Consumer Health segment which consists of various consumer health products sell directly to consumers. It also offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from six years and older; and Cotempla XR-ODT for the treatment of ADHD in patients from six to seventeen years old. In addition the company provides Karbinal ER for the treatment of seasonal and perennial allergies; and Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency. The company was formerly known as Aytu BioScience Inc. and changed its name to Aytu Biopharma Inc. in March 2021. Aytu Biopharma Inc. was incorporated in 2015 and is headquartered in Englewood Colorado.
View LessLow Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Sharpe Ratio (> 1.2)
Price Below SMA10D
Microcap (<300M USD)
Low negative Beta, possible Low Liquidity (< -0.4)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
46.2%1 month
38.5%3 months
47.5%6 months
48.3%-
9.96
0.51
0.55
0.13
1.14
0.11
-
6.11M
16.17M
16.17M
-
-4.45
-
-41.50
-47.24
10.14
5.33
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
0.30
Range1M
0.30
Range3M
0.74
Rel. volume
0.37
Price X volume
44.96K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| ICU | ICU | Biotechnology | 4.21 | 17.65M | 13.48% | n/a | -45.50% |
| Enveric Biosciences Inc | ENVB | Biotechnology | 1.97 | 17.57M | 0.36% | n/a | 0.00% |
| Inhibikase Therapeutics Inc. | IKT | Biotechnology | 1.71 | 17.06M | 0.59% | n/a | 3.49% |
| Cingulate Inc. Common Stock | CING | Biotechnology | 5.5 | 16.74M | -4.51% | n/a | 10.72% |
| Longeveron Inc. Class A Common Stock | LGVN | Biotechnology | 1.12 | 16.08M | -3.45% | n/a | 11.72% |
| VistaGen Therapeutics Inc | VTGN | Biotechnology | 0.576 | 15.58M | 2.78% | n/a | 1.90% |
| Marker Therapeutics Inc | MRKR | Biotechnology | 1.74 | 15.53M | -0.57% | n/a | 0.00% |
| Lexaria Bioscience Corp | LEXX | Biotechnology | 0.98 | 15.49M | 7.69% | n/a | 1.41% |
| HCW Biologics Inc. Common Stock | HCWB | Biotechnology | 0.3522 | 15.37M | -3.37% | n/a | -159.13% |
| DarT Bioscience Inc | DARE | Biotechnology | 1.78 | 15.21M | -2.73% | 0.12 | 218.34% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 10.4 | 15.84M | -11.56% | n/a | 204.46% |
| Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.8799 | 12.86M | -18.53% | 0.03 | 16.03% |
| REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 0.6 | 11.59M | -0.17% | n/a | 58.43% |
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.33 | 3.40M | -0.75% | n/a | 17.32% |
| Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.2276 | 2.17M | -10.25% | n/a | 19.98% |
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 2.07 | 1.14M | -0.96% | n/a | 0.00% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 1.14 | 0.53 | Expensive |
| Ent. to Revenue | 0.11 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 0.51 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 47.49 | 72.80 | Lower Risk |
| Debt to Equity | 0.55 | -1.23 | Expensive |
| Debt to Assets | 0.13 | 0.25 | Cheaper |
| Market Cap | 16.17M | 3.66B | Emerging |